Quality Clinical Research

1. Pfizer Inc. $837,500 147 payments
2. AstraZeneca Pharmaceuticals LP $350,154 12 payments
3. AbbVie, Inc. $175,179 62 payments
4. Allergan Inc. $99,001 7 payments
5. Novartis Pharmaceuticals Corporation $83,713 9 payments
6. Chiesi USA, Inc. $40,043 18 payments
7. Sanofi Pasteur Inc. $37,788 12 payments
8. Alnylam Pharmaceuticals Inc. $31,227 15 payments
9. Sekisui Diagnostics LLC $18,205 1 payment
10. Bausch Health US, LLC $17,631 2 payments

1. A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $330,963 24 payments
2. A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) $258,293 1 payment
3. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $213,251 32 payments
4. A Phase 1 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Modified Rna Vaccine Candidates Against Covid19 and Influenza in Healthy Individuals $129,955 26 payments
5. A Phase 12 Placebocontrolled Randomized Observerblind Dosefinding Firstinhuman Study to Describe the Safety Tolerability and Immunogenicity of A Respiratory Syncytial Virus RSV Vaccine in Healthy Adults $114,542 21 payments
6. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $99,001 7 payments
7. M14-433 $63,806 19 payments
8. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $59,048 8 payments
9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 $57,422 20 payments
10. A Multicenter, Randomized, Open-label, Parallel group, Functionality, and Performance Study of an Accessorized Pre-filled Syringe and Autoinjector with Home-administered Tezepelumab in Adolescent and Adult Subjects with Severe Asthma $45,323 4 payments

1. Other $5,600 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.